Symbols / VYGR
VYGR Chart
About
Voyager Therapeutics, Inc., a biotechnology company, focuses on the human genetics for the cure of neurological diseases. The company's lead product candidate is VY7523, an anti-tau antibody program for the treatment of alzheimer's disease (AD). Its product pipeline includes VY1706, a tau silencing gene therapy in preclinical trial for the treatment of alzheimer's disease; SOD1 silencing gene therapy program for treating amyotrophic lateral sclerosis in preclinical trial; and vectorized anti-amyloid antibody early research program for the treatment of AD in preclinical trial. The company is also developing VY-FXN01 for treating friedreich's ataxia; and GBA1 gene replacement program to treat parkinson's disease. In addition, it provides research program for the treatment of Huntington's disease. The company has collaboration and license agreements with Alexion; AstraZeneca Ireland Limited; Novartis Pharma AG; and Neurocrine Biosciences, Inc. for the treatment of various other diseases of the central nervous system. Voyager Therapeutics, Inc. was incorporated in 2013 and is headquartered in Lexington, Massachusetts.
Fundamentals
Scroll to Statements| Sector | Healthcare | Industry | Biotechnology | Market Cap | 211.84M |
| Enterprise Value | 39.61M | Income | -126.78M | Sales | 31.32M |
| Book/sh | 3.96 | Cash/sh | 3.76 | Dividend Yield | — |
| Payout | 0.00% | Employees | 172 | IPO | — |
| P/E | — | Forward P/E | -2.44 | PEG | — |
| P/S | 6.76 | P/B | 0.96 | P/C | — |
| EV/EBITDA | -0.29 | EV/Sales | 1.26 | Quick Ratio | 6.00 |
| Current Ratio | 6.19 | Debt/Eq | 17.45 | LT Debt/Eq | — |
| EPS (ttm) | -2.17 | EPS next Y | -1.56 | EPS Growth | — |
| Revenue Growth | -45.70% | Earnings | 2026-03-16 | ROA | -24.54% |
| ROE | -46.09% | ROIC | — | Gross Margin | 0.00% |
| Oper. Margin | -228.91% | Profit Margin | 0.00% | Shs Outstand | 55.60M |
| Shs Float | 43.38M | Short Float | 7.32% | Short Ratio | 5.30 |
| Short Interest | — | 52W High | 5.55 | 52W Low | 2.65 |
| Beta | 1.33 | Avg Volume | 540.66K | Volume | 12.72K |
| Target Price | $15.00 | Recom | Strong_buy | Prev Close | $3.78 |
| Price | $3.81 | Change | 0.79% |
Valuation Models
Price estimates from analyst targets and simple models.
1. Analyst consensus
$15.00
Mean price target
2. Current target
$3.81
Latest analyst target
3. DCF / Fair value
$-20.36
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$3.81
Low
$8.00
High
$25.00
Mean
$15.00
Latest analyst rating changes
| Date | Action | Analyst | Rating Change | Price Target |
|---|---|---|---|---|
| 2025-11-12 | main | HC Wainwright & Co. | Buy → Buy | $25 |
| 2025-09-15 | reit | HC Wainwright & Co. | Buy → Buy | $30 |
| 2025-08-07 | main | Wedbush | Outperform → Outperform | $8 |
| 2025-04-08 | reit | HC Wainwright & Co. | Buy → Buy | $30 |
| 2025-03-13 | main | Canaccord Genuity | Buy → Buy | $12 |
| 2025-03-13 | reit | HC Wainwright & Co. | Buy → Buy | $30 |
| 2025-03-12 | main | Wells Fargo | Overweight → Overweight | $10 |
| 2025-03-12 | reit | Wedbush | Outperform → Outperform | — |
| 2025-03-12 | reit | Cantor Fitzgerald | Overweight → Overweight | — |
| 2025-03-03 | reit | HC Wainwright & Co. | Buy → Buy | $30 |
| 2025-01-27 | reit | HC Wainwright & Co. | Buy → Buy | $30 |
| 2025-01-10 | init | Cantor Fitzgerald | — → Overweight | $6 |
| 2024-12-02 | init | Citigroup | — → Buy | $12 |
| 2024-11-14 | main | Canaccord Genuity | Buy → Buy | $14 |
| 2024-11-14 | reit | HC Wainwright & Co. | Buy → Buy | $30 |
| 2024-10-24 | reit | HC Wainwright & Co. | Buy → Buy | $30 |
| 2024-10-16 | init | Leerink Partners | — → Outperform | $15 |
| 2024-08-20 | reit | HC Wainwright & Co. | Buy → Buy | $30 |
| 2024-08-07 | main | Wedbush | Neutral → Neutral | $7 |
| 2024-07-31 | reit | HC Wainwright & Co. | Buy → Buy | $30 |
- Voyager Therapeutics (VYGR): Strong Q3 Prompts Bullish Coverage - Yahoo Finance Wed, 10 Dec 2025 08
- With Voyager Therapeutics Stock Sliding, Have You Assessed The Risk? - Trefis Sat, 20 Dec 2025 08
- Earnings Update: Voyager Therapeutics, Inc. (NASDAQ:VYGR) Just Reported Its Third-Quarter Results And Analysts Are Updating Their Forecasts - simplywall.st Fri, 14 Nov 2025 08
- Voyager to Present at Upcoming Investor Conferences - GlobeNewswire Mon, 09 Feb 2026 13
- New Analyst Forecast: $VYGR Given $25.0 Price Target - Quiver Quantitative Wed, 12 Nov 2025 08
- Top Voyager Therapeutics Executives Quietly Unload Company Shares - TipRanks hu, 12 Feb 2026 02
- Voyager Therapeutics: Navigating AAV Headwinds And A Long Road For VY7523 (Downgrade) - Seeking Alpha Fri, 06 Jun 2025 07
- Voyager Therapeutics (VYGR) Soars 11.6%: Is Further Upside Left in the Stock? - Yahoo Finance hu, 09 Oct 2025 07
- Benign Growth For Voyager Therapeutics, Inc. (NASDAQ:VYGR) Underpins Stock's 26% Plummet - simplywall.st Sat, 15 Nov 2025 08
- Voyager Therapeutics Q2 2025 Financial and Operating Results - TradingView Wed, 06 Aug 2025 07
- Voyager Therapeutics Announces Chief Medical Officer Resignation - TipRanks hu, 12 Feb 2026 08
- Owning 44% shares,institutional owners seem interested in Voyager Therapeutics, Inc. (NASDAQ:VYGR), - Yahoo Finance ue, 28 Oct 2025 07
- Voyager Reports Third Quarter 2025 Financial and Operating Results - GlobeNewswire Mon, 10 Nov 2025 08
- It's Unlikely That The CEO Of Voyager Therapeutics, Inc. (NASDAQ:VYGR) Will See A Huge Pay Rise This Year - simplywall.st ue, 27 May 2025 07
- We're A Little Worried About Voyager Therapeutics' (NASDAQ:VYGR) Cash Burn Rate - Yahoo Finance Mon, 24 Nov 2025 08
Insider Transactions
| Date | Shares | Value | Url | Text | Insider | Position | Transaction | Start Date | Ownership |
|---|---|---|---|---|---|---|---|---|---|
| 0 | 11732 | 40006 | — | Sale at price 3.41 per share. | SANDROCK ALFRED | Chief Executive Officer | — | 2026-02-18 00:00:00 | D |
| 1 | 3882 | 13354 | — | Sale at price 3.44 per share. | SWARTZ ROBIN | Chief Operating Officer | — | 2026-02-18 00:00:00 | D |
| 2 | 3301 | 11355 | — | Sale at price 3.44 per share. | CARTER TODD ALFRED | Officer | — | 2026-02-18 00:00:00 | D |
| 3 | 12192 | 46086 | — | Sale at price 3.78 per share. | SANDROCK ALFRED | Chief Executive Officer | — | 2026-02-10 00:00:00 | D |
| 4 | 4569 | 17591 | — | Sale at price 3.85 per share. | SWARTZ ROBIN | Chief Operating Officer | — | 2026-02-10 00:00:00 | D |
| 5 | 3525 | 13571 | — | Sale at price 3.85 per share. | CARTER TODD ALFRED | Officer | — | 2026-02-10 00:00:00 | D |
| 6 | 86250 | — | — | Stock Award(Grant) at price 0.00 per share. | SANDROCK ALFRED | Chief Executive Officer | — | 2026-02-06 00:00:00 | D |
| 7 | 32250 | — | — | Stock Award(Grant) at price 0.00 per share. | JORGENSEN NATHAN D. | Chief Financial Officer | — | 2026-02-06 00:00:00 | D |
| 8 | 45000 | — | — | Stock Award(Grant) at price 0.00 per share. | SWARTZ ROBIN | Chairman of the Board | — | 2026-02-06 00:00:00 | D |
| 9 | 33000 | — | — | Stock Award(Grant) at price 0.00 per share. | CARTER TODD ALFRED | Officer | — | 2026-02-06 00:00:00 | D |
Financials
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| TaxEffectOfUnusualItems | 0.00 | 0.00 | 0.00 | 0.00 |
| TaxRateForCalcs | 0.21 | 0.01 | 0.00 | 0.00 |
| NormalizedEBITDA | -78.56M | 126.45M | -44.65M | -68.45M |
| NetIncomeFromContinuingOperationNetMinorityInterest | -65.00M | 132.33M | -46.41M | -71.20M |
| ReconciledDepreciation | 4.73M | 4.44M | 6.19M | 5.17M |
| EBITDA | -78.56M | 126.45M | -44.65M | -68.45M |
| EBIT | -83.29M | 122.01M | -50.84M | -73.62M |
| NetInterestIncome | 18.33M | 11.72M | 1.79M | -390.00K |
| NormalizedIncome | -65.00M | 132.33M | -46.41M | -71.20M |
| NetIncomeFromContinuingAndDiscontinuedOperation | -65.00M | 132.33M | -46.41M | -71.20M |
| TotalExpenses | 163.29M | 127.99M | 91.74M | 111.03M |
| TotalOperatingIncomeAsReported | -83.29M | 122.01M | -50.84M | -73.62M |
| DilutedAverageShares | 57.67M | 44.57M | 38.36M | 37.67M |
| BasicAverageShares | 57.67M | 43.02M | 38.36M | 37.67M |
| DilutedEPS | -1.13 | 2.97 | -1.21 | -1.89 |
| BasicEPS | -1.13 | 3.08 | -1.21 | -1.89 |
| DilutedNIAvailtoComStockholders | -65.00M | 132.33M | -46.41M | -71.20M |
| NetIncomeCommonStockholders | -65.00M | 132.33M | -46.41M | -71.20M |
| NetIncome | -65.00M | 132.33M | -46.41M | -71.20M |
| NetIncomeIncludingNoncontrollingInterests | -65.00M | 132.33M | -46.41M | -71.20M |
| NetIncomeContinuousOperations | -65.00M | 132.33M | -46.41M | -71.20M |
| TaxProvision | 665.00K | 1.41M | 16.00K | 0.00 |
| PretaxIncome | -64.34M | 133.74M | -46.39M | -71.20M |
| OtherIncomeExpense | 622.00K | 3.00K | 2.65M | 2.81M |
| OtherNonOperatingIncomeExpenses | 622.00K | 3.00K | 2.65M | 2.81M |
| NetNonOperatingInterestIncomeExpense | 18.33M | 11.72M | 1.79M | -390.00K |
| TotalOtherFinanceCost | -18.33M | -11.72M | -1.79M | 390.00K |
| OperatingIncome | -83.29M | 122.01M | -50.84M | -73.62M |
| OperatingExpense | 163.29M | 127.99M | 91.74M | 111.03M |
| ResearchAndDevelopment | 127.37M | 92.17M | 60.76M | 73.79M |
| SellingGeneralAndAdministration | 35.92M | 35.82M | 30.98M | 37.25M |
| GeneralAndAdministrativeExpense | 35.92M | 35.82M | 30.98M | 37.25M |
| OtherGandA | 35.92M | 35.82M | 30.98M | 37.25M |
| TotalRevenue | 80.00M | 250.01M | 40.91M | 37.41M |
| OperatingRevenue | 80.00M | 250.01M | 40.91M | 37.41M |
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| OrdinarySharesNumber | 54.73M | 44.04M | 38.61M | 37.92M |
| ShareIssued | 54.73M | 44.04M | 38.61M | 37.92M |
| TotalDebt | 43.73M | 20.29M | 23.13M | 44.18M |
| TangibleBookValue | 299.76M | 236.32M | 59.02M | 95.06M |
| InvestedCapital | 299.76M | 236.32M | 59.02M | 95.06M |
| WorkingCapital | 227.02M | 255.18M | 51.91M | 85.72M |
| NetTangibleAssets | 299.76M | 236.32M | 59.02M | 95.06M |
| CapitalLeaseObligations | 43.73M | 20.29M | 23.13M | 44.18M |
| CommonStockEquity | 299.76M | 236.32M | 59.02M | 95.06M |
| TotalCapitalization | 299.76M | 236.32M | 59.02M | 95.06M |
| TotalEquityGrossMinorityInterest | 299.76M | 236.32M | 59.02M | 95.06M |
| StockholdersEquity | 299.76M | 236.32M | 59.02M | 95.06M |
| GainsLossesNotAffectingRetainedEarnings | -407.00K | -48.00K | -219.00K | -138.00K |
| OtherEquityAdjustments | -407.00K | -48.00K | -219.00K | -138.00K |
| RetainedEarnings | -326.18M | -261.18M | -393.51M | -347.10M |
| AdditionalPaidInCapital | 626.30M | 497.51M | 452.71M | 442.26M |
| CapitalStock | 55.00K | 44.00K | 38.00K | 38.00K |
| CommonStock | 55.00K | 44.00K | 38.00K | 38.00K |
| PreferredStock | 0.00 | 0.00 | 0.00 | 0.00 |
| TotalLiabilitiesNetMinorityInterest | 93.29M | 114.96M | 100.34M | 98.80M |
| TotalNonCurrentLiabilitiesNetMinorityInterest | 43.50M | 50.45M | 27.75M | 47.82M |
| OtherNonCurrentLiabilities | 1.00M | 1.00M | 1.00M | 1.00M |
| NonCurrentDeferredLiabilities | 6.00M | 32.36M | 6.45M | 8.21M |
| NonCurrentDeferredRevenue | 6.00M | 32.36M | 6.45M | 8.21M |
| LongTermDebtAndCapitalLeaseObligation | 36.50M | 17.09M | 20.29M | 38.61M |
| LongTermCapitalLeaseObligation | 36.50M | 17.09M | 20.29M | 38.61M |
| CurrentLiabilities | 49.79M | 64.51M | 72.59M | 50.98M |
| CurrentDeferredLiabilities | 24.39M | 42.88M | 59.38M | 33.89M |
| CurrentDeferredRevenue | 24.39M | 42.88M | 59.38M | 33.89M |
| CurrentDebtAndCapitalLeaseObligation | 7.23M | 3.20M | 2.83M | 5.57M |
| CurrentCapitalLeaseObligation | 7.23M | 3.20M | 2.83M | 5.57M |
| PensionandOtherPostRetirementBenefitPlansCurrent | 6.75M | 6.61M | 4.56M | 5.02M |
| PayablesAndAccruedExpenses | 11.41M | 11.81M | 5.82M | 6.50M |
| CurrentAccruedExpenses | 7.42M | 10.21M | 3.26M | 5.93M |
| Payables | 4.00M | 1.60M | 2.57M | 574.00K |
| AccountsPayable | 4.00M | 1.60M | 2.57M | 574.00K |
| TotalAssets | 393.05M | 351.28M | 159.36M | 193.85M |
| TotalNonCurrentAssets | 116.24M | 31.60M | 34.86M | 57.16M |
| OtherNonCurrentAssets | 2.87M | 1.59M | 1.51M | 1.78M |
| NonCurrentPrepaidAssets | 1.78M | |||
| InvestmentsAndAdvances | 65.70M | 0.00 | ||
| InvestmentinFinancialAssets | 65.70M | 0.00 | ||
| AvailableForSaleSecurities | 65.70M | |||
| NetPPE | 47.66M | 30.00M | 33.34M | 55.38M |
| AccumulatedDepreciation | -15.96M | -15.04M | -17.21M | -15.91M |
| GrossPPE | 63.62M | 45.04M | 50.55M | 71.29M |
| Leases | 6.49M | 7.11M | 12.55M | 15.70M |
| ConstructionInProgress | 0.00 | |||
| OtherProperties | 54.80M | 35.31M | 35.66M | 53.07M |
| MachineryFurnitureEquipment | 2.33M | 2.62M | 2.33M | 2.52M |
| Properties | 0.00 | 0.00 | 0.00 | 0.00 |
| CurrentAssets | 276.81M | 319.68M | 124.50M | 136.70M |
| OtherCurrentAssets | 2.87M | 2.63M | 4.23M | 1.70M |
| HedgingAssetsCurrent | 0.00 | |||
| PrepaidAssets | 2.76M | 1.73M | 779.00K | 1.71M |
| Receivables | 4.49M | 84.45M | 639.00K | 748.00K |
| DuefromRelatedPartiesCurrent | 676.00K | 3.34M | 257.00K | 732.00K |
| AccruedInterestReceivable | 2.31M | 964.00K | 382.00K | 16.00K |
| AccountsReceivable | 1.50M | 80.15M | 0.00 | 732.00K |
| CashCashEquivalentsAndShortTermInvestments | 266.68M | 230.88M | 118.85M | 132.54M |
| OtherShortTermInvestments | 195.32M | 162.07M | 19.89M | 15.11M |
| CashAndCashEquivalents | 71.37M | 68.80M | 98.96M | 117.43M |
| CashEquivalents | 59.66M | 65.59M | 91.72M | |
| CashFinancial | 11.71M | 3.21M | 7.24M |
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| FreeCashFlow | -18.83M | 74.66M | -15.00M | -55.13M |
| IssuanceOfCapitalStock | 112.78M | 31.12M | 0.00 | 0.00 |
| CapitalExpenditure | -3.52M | -3.26M | -2.49M | -1.61M |
| EndCashPosition | 74.24M | 70.39M | 100.47M | 119.21M |
| BeginningCashPosition | 70.39M | 100.47M | 119.21M | 106.22M |
| ChangesInCash | 3.85M | -30.08M | -18.74M | 12.99M |
| FinancingCashFlow | 114.02M | 33.65M | 1.11M | 612.00K |
| CashFlowFromContinuingFinancingActivities | 114.02M | 33.65M | 1.11M | 612.00K |
| ProceedsFromStockOptionExercised | 1.24M | 2.52M | 1.11M | 612.00K |
| NetCommonStockIssuance | 112.78M | 31.12M | 0.00 | 0.00 |
| CommonStockIssuance | 112.78M | 31.12M | 0.00 | 0.00 |
| InvestingCashFlow | -94.86M | -141.64M | -7.34M | 65.91M |
| CashFlowFromContinuingInvestingActivities | -94.86M | -141.64M | -7.34M | 65.91M |
| NetInvestmentPurchaseAndSale | -91.34M | -138.39M | -4.85M | 67.52M |
| SaleOfInvestment | 374.35M | 85.58M | 50.00M | 82.63M |
| PurchaseOfInvestment | -465.69M | -223.97M | -54.85M | -15.12M |
| NetPPEPurchaseAndSale | -3.52M | -3.26M | -2.49M | -1.61M |
| SaleOfPPE | 0.00 | |||
| PurchaseOfPPE | -3.52M | -3.26M | -2.49M | -1.61M |
| OperatingCashFlow | -15.31M | 77.92M | -12.51M | -53.52M |
| CashFlowFromContinuingOperatingActivities | -15.31M | 77.92M | -12.51M | -53.52M |
| ChangeInWorkingCapital | 34.86M | -66.56M | 20.47M | 3.29M |
| ChangeInOtherWorkingCapital | -44.84M | 9.41M | 23.73M | -1.72M |
| ChangeInOtherCurrentLiabilities | -3.32M | -2.83M | -3.92M | -3.43M |
| ChangeInOtherCurrentAssets | 4.60M | 1.98M | 3.31M | 2.67M |
| ChangeInPayablesAndAccruedExpense | -260.00K | 8.04M | -1.16M | -3.40M |
| ChangeInAccruedExpense | -2.65M | 9.01M | -3.15M | -3.33M |
| ChangeInPayable | 2.39M | -962.00K | 1.99M | -60.00K |
| ChangeInAccountPayable | 2.39M | -962.00K | 1.99M | -60.00K |
| ChangeInPrepaidAssets | -2.63M | 76.00K | -1.97M | 1.88M |
| ChangeInReceivables | 81.31M | -83.23M | 475.00K | 7.28M |
| ChangesInAccountReceivables | 78.65M | -80.15M | 0.00 | 0.00 |
| OtherNonCashItems | -2.47M | -2.46M | ||
| StockBasedCompensation | 14.79M | 11.15M | 9.34M | 11.32M |
| AssetImpairmentCharge | 2.78M | 0.00 | 0.00 | |
| AmortizationOfSecurities | -7.97M | -3.63M | -16.00K | 349.00K |
| DepreciationAmortizationDepletion | 4.73M | 4.44M | 6.19M | 5.17M |
| DepreciationAndAmortization | 4.73M | 4.44M | 6.19M | 5.17M |
| Depreciation | 4.73M | 4.44M | 6.19M | 5.17M |
| OperatingGainsLosses | 510.00K | 178.00K | 377.00K | |
| GainLossOnSaleOfPPE | 510.00K | 178.00K | 377.00K | 0.00 |
| NetIncomeFromContinuingOperations | -65.00M | 132.33M | -46.41M | -71.20M |
SEC Filings
Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.
Public Trades for VYGR
| Date | User | Asset | Broker | Type | Position Size | Entry Price | Patterns |
|---|